KCT0008917招募中Unknown
A Multicenter, Adaptive, Randomized, Controlled Trial Platform To Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized Patients with Respiratory Infections
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1. Confirmation of SARS-CoV2 infection by nucleic acid test (NAT) or equivalent non-NAT test [list of approved tests in the PIM] collected within 14 days of randomization.
- •2. Requiring hospitalization for the management of COVID-19.
- •3. Has evidence of COVID-19 pneumonia (PNA) defined as either:
- •a. Receiving supplemental low flow oxygen, >0 L/min and =2 L/min, with evidence of airspace disease on chest imaging (X-ray, computer tomography or ultrasound).OR
- •b. Receiving supplemental low flow oxygen, >2 L/min and <10 L/min.
- •4. Currently receiving or planned to receive (ordered) one IM drug (for example, a corticosteroid or baricitinib, but NOT abatacept) as part of treatment of COVID-19 prior to randomization.
- •5. Has started supplemental oxygen for the treatment of COVID-19 within the past 5 calendar days. Patients on home oxygen are eligible if current oxygen flow rate is increased from pre-COVID-19 level and all other study criteria are met.
- •6. Investigator agrees that the pneumonia is due to COVID-19.
排除标准
- •1. Oxygen requirement of 10 L/min or more of low flow oxygen (or equivalent if using Venturi mask, etc.), or requiring high-flow oxygen (HFNO), non-invasive ventilation (NIV), invasive mechanical ventilation (IMV) or ECMO.
- •2. Received more than one baseline IM for treatment of the current COVID-19
- •infection at the time of trial enrollment (examples: corticosteroid, baricitinib,
- •tocilizumab, anakinra, abatacept, or infliximab).
- •3. Participant anticipated to not meet all inclusion criteria within 24 hours of randomization in the opinion of the investigator.
- •4. Allergy to investigational agent.
- •5. Neutropenia: absolute neutrophil count <1000 cells/µL (<1.0 x 103/µL or <1.0 x 109/L) on most recent lab within 2 calendar days of randomization.
- •6. Lymphopenia: absolute lymphocyte count <200 cells/µL (<0.20 x 103/µL or <0.20 x 109/L) on most recent lab within 2 calendar days of randomization.
- •7. Known or suspected active or recent serious infection (bacterial, fungal, viral, or parasitic infection, excepting SARS-CoV-2) that in the opinion of the investigator could constitute a risk when taking investigational agent. Note:
- •Broad spectrum empiric antibiotic usage does not exclude participation.
- •8. Known or suspected history of untreated tuberculosis (TB). TB diagnosis may be suspected based on medical history and concomitant therapies that would suggest TB infection. Participants are also excluded if they have known, latent
- •TB treated for less than 4 weeks with appropriate anti-tuberculosis therapy per local guidelines (by history only, no screening required).
- •9. Received any live vaccine (or live attenuated) within 3 months before screening or intend to receive a live vaccine (or live attenuated) during the trial. Use of prior non-live (inactivated) vaccinations is allowed for all participants, including any vaccine for COVID-19.
- •10.Pre-existing immunomodulation or immunosuppression that meets any of the following:
- •a. Participant has received abatacept for an indication other than COVID19 within 5 half-lives (65 days) of enrollment (Abatacept elimination halflife is 13.1 days.)
- •b. Participant is receiving immune modulatory therapy for autoimmune, transplant management or another indication AND has one or more of the following:
- •i. evidence of active infection (other than COVID-19) or
- •ii. has required reduction in their immune modulatory therapy in the
- •preceding 6 months due to infectious complication (routine reduction as SOC is not an exclusion) or
- •iii. has required intensification in immune modulatory therapy within the preceding 6 months due to organ rejection/worsening underlying disease status (e.g., intensification with an additional agent on top of usual immunosuppressive regimen).
- •c. Participant has recently received or is anticipated to require immune modulatory agents for their underlying disease including chemotherapeutic treatments likely to induce neutropenia or lymphopenia.
- •d. Participant has untreated advanced HIV (known CD4 <200 cells/mm3 in the past 6 months) AND is not established on antiretroviral therapy.
- •11.Pregnancy or intention to become pregnant within 60 days of randomization.
- •12.Currently breastfeeding.
- •13.Co-enrollment in other trials not predetermined to be compatible with this trial.
- •14.In the investigator’s judgment, the participant has any advanced organ dysfunction that would not make participation appropriate.
- •15.The treating clinician expects inability to participate in trial p
研究者
相似试验
招募中
3 期
STRIVE Appendix E1: S-217622 (Ensitrelvir)JPRN-jRCT2031220667Ohmagari Norio50
招募中
1 期
A Multicenter, Adaptive, Randomized, Controlled Trial Platform to Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized Patients with Respiratory Infections: Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE) - Shionogi Protease Inhibitor (S-217622)COVID-19MedDRA version: 23.0Level: PTClassification code: 10084268Term: COVID-19 Class: 100000004862CTIS2022-501020-19-01niversity Of Minnesota1,520
招募中
1 期
A Multicenter, Adaptive, Randomized, Controlled Trial Platform to Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized Patients with Respiratory Infections: Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE) - Immune Modulation Strategy TrialCOVID-19MedDRA version: 23.0Level: PTClassification code: 10084268Term: COVID-19 Class: 100000004862CTIS2023-504487-41-00niversity Of Minnesota1,520
招募中
Unknown
A multicenter, Adaptive, Randomised, Controlled Trial Platform to Evaluated Safety and Efficacy of Strategies and Treatments for Hospitalized Patients with Respiratory InfectionsCodes for special purposesKCT0008328Seoul National University Bundang Hospital50
进行中（未招募）
1 期
Evaluation of Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19Patients hospitalized for COVID-19 and enrolled within 72 hours of hospital admittance or 72 hours of positive COVID testMedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-004285-19-ITCONSORZIO FUTURO IN RICERCA2,000